Keryx Biopharmaceuticals (NASDAQ:KERX) and TIGENIX/S (NASDAQ:TIG) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.
Valuation & Earnings
This table compares Keryx Biopharmaceuticals and TIGENIX/S’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Keryx Biopharmaceuticals||$60.64 million||5.67||-$163.44 million||($0.88)||-3.82|
Institutional and Insider Ownership
69.0% of Keryx Biopharmaceuticals shares are owned by institutional investors. Comparatively, 4.4% of TIGENIX/S shares are owned by institutional investors. 1.6% of Keryx Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This table compares Keryx Biopharmaceuticals and TIGENIX/S’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent recommendations and price targets for Keryx Biopharmaceuticals and TIGENIX/S, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Keryx Biopharmaceuticals presently has a consensus price target of $6.75, indicating a potential upside of 100.89%. Given Keryx Biopharmaceuticals’ higher possible upside, research analysts plainly believe Keryx Biopharmaceuticals is more favorable than TIGENIX/S.
Keryx Biopharmaceuticals beats TIGENIX/S on 5 of the 7 factors compared between the two stocks.
Keryx Biopharmaceuticals Company Profile
Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis. The company has strategic alliances with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of ferric citrate in Japan; and with Panion & BF Biotech, Inc. for the development and marketing of ferric citrate. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.
TIGENIX/S Company Profile
TiGenix NV, a biopharmaceutical company, develops and commercializes therapeutics from its proprietary technology platforms of allogeneic or donor derived stem cells. Its stem cell programs are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory, and heart diseases. The company's lead product candidate is the Cx601, which completed Phase III clinical trials for the treatment of complex perianal fistulas in patients suffering from Crohn's disease. It also engages in developing Cx611, a clinical stage product candidate from its expanded adipose-derived stem cell-based (eASC-based) technology platform, which completed a Phase I study in sepsis and a Phase Ib/IIa trial for the treatment of refractory rheumatoid arthritis; and Cx621, which has completed a Phase I trial for the treatment of intra lymphatic administration of allogeneic eASCs. It is also developing AlloCSC-01, a product candidate based on the CSC-based platform, which has completed a Phase I/II study in acute myocardial infarction. The company has operations in Belgium, Spain, and the United States. TiGenix NV was founded in 2000 and is headquartered in Leuven, Belgium. As of July 3, 2018, TiGenix NV operates as a subsidiary of Takeda Pharmaceutical Company Limited.
Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.